XML 35 R24.htm IDEA: XBRL DOCUMENT v3.25.2
Restructuring, Impairment and Related Charges
6 Months Ended
Jun. 30, 2025
Restructuring and Related Activities [Abstract]  
Restructuring, Impairment and Related Charges
16.
Restructuring, Impairment and Related Charges

From time to time management may decide to restructure our business to streamline costs and expenses. We also continue to explore business opportunities to partner, divest or delay certain research and development programs to drive operational changes in our business processes, efficiencies and cost savings to advance our corporate strategy and development programs. We expect that these initiatives, including restructuring, will reduce our operating expenses.

Upon entering into the Bayer License Agreement and termination of the Navire-BMS License Agreement in March 2024 (refer to Note 11 for details regarding these transactions) and our announced decision to cease pursuing development of BBP-631 for CAH in September 2024, we committed to restructuring plans to reprioritize and advance our corporate strategy and development programs. The restructuring plans included, among other components, consolidation and rationalization of our facilities, reprioritization of development programs and the reduction in our workforce. We estimate that remaining restructuring charges associated with previously announced programs are immaterial, consisting primarily of wind-down costs, exit costs, and other related expenses. Our estimate of the costs is subject to certain assumptions and actual results may differ from those estimates or assumptions. We may also incur additional costs that are not currently foreseeable as we continue to evaluate our restructuring alternatives to drive operational changes in business processes, efficiencies and cost savings.

“Restructuring, impairment and related charges” included on our condensed consolidated statements of operations for the three and six months ended June 30, 2025 and 2024 consisted of the following:

 

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

 

 

(in thousands)

 

Winding down, exit and other related costs

 

$

712

 

 

$

2,353

 

 

$

1,146

 

 

$

3,517

 

Severance and employee-related costs

 

 

93

 

 

 

538

 

 

 

229

 

 

 

2,503

 

Long-lived assets impairments and write-offs

 

 

 

 

 

 

 

 

 

 

 

271

 

Total

 

$

805

 

 

$

2,891

 

 

$

1,375

 

 

$

6,291

 

 

 

The following table summarizes the activity related to the restructuring liabilities associated with our restructuring plans for the six months ended June 30, 2025 and 2024:

 

 

 

Six Months Ended June 30,

 

 

 

2025

 

 

2024

 

 

 

(in thousands)

 

Beginning balance

 

$

1,848

 

 

$

55

 

Restructuring, impairment and related charges

 

 

1,375

 

 

 

6,291

 

Cash payments

 

 

(2,648

)

 

 

(3,121

)

Noncash activities

 

 

(49

)

 

 

(318

)

Ending balance

 

$

526

 

 

$

2,907

 

 

Restructuring liabilities are presented on our condensed consolidated balance sheets as follows:

 

 

 

June 30, 2025

 

 

December 31, 2024

 

 

 

(in thousands)

 

Accounts payable

 

$

81

 

 

$

330

 

Accrued compensation and benefits

 

 

103

 

 

 

332

 

Accrued research and development liabilities

 

 

314

 

 

 

1,020

 

Other current liabilities

 

 

28

 

 

 

166

 

Total

 

$

526

 

 

$

1,848